Chugai Seiyaku Kabushiki Kaisha

Jsr Corporation

F. Hoffmann-La Roche Ag

Jsr Life Sciences Corporation

Jun Amano

Toshihiko Ohtomo

Tetsuji Yamaguchi

Hideki Adachi

Tsukasa Suzuki

Mikiko Nakamura

Ya-Chi Chen

Motoaki Mizuuchi

Seiki Wakui

The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy

The present invention relates to a method for assaying soluble GPC3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the N-terminal region of GPC3 protein.

Method for assaying soluble GPC3 protein

Growing community of inventors

Shizuoka, Japan

Jun Amano